摘要
人类原发性免疫缺陷病(PIDs)是一大类罕见疾病,具有很强的遗传和表型异质性。遗传定义了大量的PID,这对于理解疾病的分子基础和精准医学的发展具有重要影响。由于所涉及的过程的长度和成本,长期以来已经发现和开发用于罕见疾病的新疗法。由于刺激性的监管和支持性报销环境使得可行的商业模式成为可能,利息增加了。生物医学和计算科学的进步使得能够开发合理的,设计的方法来识别已经批准的药物的新指示,从而允许更快地递送新药物。药物重新定位基于疾病的临床类比或理解药物作用的分子模式和疾病的机制。所有这些都是精准医学发展的基础。
关键词: 药物重新定位,重新定位,原发性免疫缺陷病; 儿科,新疗法,罕见疾病。
Current Medicinal Chemistry
Title:Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine
Volume: 25 Issue: 24
关键词: 药物重新定位,重新定位,原发性免疫缺陷病; 儿科,新疗法,罕见疾病。
摘要: Human primary immunodeficiency diseases (PIDs) are a large group of rare diseases and are characterized by a great genetic and phenotypic heterogeneity. A large subset of PIDs is genetically defined, which has a crucial impact for the understanding of the molecular basis of disease and the development of precision medicine.
Discovery and development of new therapies for rare diseases has long been de-privileged due to the length and cost of the processes involved. Interest has increased due to stimulatory regulatory and supportive reimbursement environments enabling viable business models.
Advancements in biomedical and computational sciences enable the development of rational, designed approaches for identification of novel indications of already approved drugs allowing faster delivery of new medicines. Drug repositioning is based either on clinical analogies of diseases or on understanding of the molecular mode of drug action and mechanisms of the disease. All of these are the basis for the development of precision medicine.
Export Options
About this article
Cite this article as:
Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine, Current Medicinal Chemistry 2018; 25 (24) . https://dx.doi.org/10.2174/0929867324666170830101215
DOI https://dx.doi.org/10.2174/0929867324666170830101215 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Synthetic Approaches to the Multifunctional Drug Ebselen and Analogs: Past and Present
Mini-Reviews in Organic Chemistry Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Effects of N-Acetyl-L-Cysteine and Hyaluronic Acid on HBOC-201- Induced Systemic and Cerebral Vasoconstriction in the Rat
Current Drug Discovery Technologies New Hybrid Scaffolds based on Hydrazinyl Thiazole Substituted Coumarin; As Novel Leads of Dual Potential; In Vitro α-Amylase Inhibitory and Antioxidant (DPPH and ABTS Radical Scavenging) Activities
Medicinal Chemistry Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Clinical Assessment of Carotid Atherosclerosis Inflammation by Positron Emission Tomography
Current Molecular Medicine Preterm Birth, Inflammation and Infection: New Alternative Strategies for their Prevention
Current Pharmaceutical Biotechnology Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Antioxidants in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Molecular Aspects of Drug Recognition by Specific T Cells
Current Drug Targets PD1/PD-L1 Axis in Uro-oncology
Current Drug Targets Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design